NCT03991780 (FOSTAMR) is a Phase 1, PHASE2 clinical trial of Fostamatinib in Renal Transplant Rejection, sponsored by Imperial College London.

Who is sponsoring NCT03991780?

NCT03991780 is sponsored by Imperial College London.

What drugs are being tested in NCT03991780?

Interventions in NCT03991780: Fostamatinib.

What condition does NCT03991780 study?

NCT03991780 studies Renal Transplant Rejection.

Is NCT03991780 still recruiting?

NCT03991780 is currently active, enrolled. Last updated 25 November 2024.

Last reviewed 2024-11-25 · How we verify

NCT03991780: FOSTAMR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection

Active, enrolled Phase 1, PHASE2 Last updated 25 November 2024

What this trial tests

Phase 1, PHASE2 trial testing Fostamatinib in Renal Transplant Rejection in 8 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

8 May 2019

Primary endpoint
5 April 2023

15 October 2025

Quick facts

Lead sponsor	Imperial College London
Phase	Phase 1, PHASE2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	8
Start date	8 May 2019
Primary completion	5 April 2023
Estimated completion	15 October 2025
Sites	1 location across United Kingdom

Drugs / interventions tested

Fostamatinib (FOSTAMATINIB) — full drug profile →

Conditions studied

Renal Transplant Rejection — all drugs for Renal Transplant Rejection →

Sponsor

Imperial College London

Who can join

18 and older, any sex, with Renal Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A Phase 2, Pilot Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection in Renal Transplantation

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Kinase inhibition in autoimmunity and inflammation.
Zarrin AA, Bao K, Lupardus P, Vucic D. · · 2021 · cited 302× · PMID 33077936 · DOI 10.1038/s41573-020-0082-8
Antibody-mediated rejection: prevention, monitoring and treatment dilemmas.
Rodriguez-Ramirez S, Al Jurdi A, Konvalinka A, Riella LV. · · 2022 · cited 32× · PMID 35950887 · DOI 10.1097/mot.0000000000001011
Chronic Rejection After Kidney Transplantation.
Diebold M, Mayer KA, Hidalgo L, Kozakowski N, et al · · 2025 · cited 20× · PMID 39192468 · DOI 10.1097/tp.0000000000005187
Targeted spleen modulation: a novel strategy for next-generation disease immunotherapy.
Dong W, Li Y, Fei Q, Li S, et al · · 2025 · cited 16× · PMID 40225564 · DOI 10.7150/thno.111116
Inhibition of Spleen Tyrosine Kinase Restores Glucocorticoid Sensitivity to Improve Steroid-Resistant Asthma.
Liu Q, Hua L, Bao C, Kong L, et al · · 2022 · cited 13× · PMID 35600871 · DOI 10.3389/fphar.2022.885053
Antibody-mediated rejection-treatment standard.
Böhmig GA, Naesens M, Viklicky O, Thaunat O, et al · · 2025 · cited 5× · PMID 40440205 · DOI 10.1093/ndt/gfaf097
New Immunosuppressants in Pediatric Kidney Transplantation: What's in the Pipeline for Kids?
Tönshoff B, Patry C, Fichtner A, Höcker B, et al · · 2025 · cited 4× · PMID 39711054 · DOI 10.1111/petr.70008
T-B Collaboration in Autoimmunity, Infection, and Transplantation.
DiToro D, Murakami N, Pillai S. · · 2024 · cited 3× · PMID 37314442 · DOI 10.1097/tp.0000000000004671

Verify or expand the search:

Other trials of Fostamatinib

Trials testing the same drug.

NCT06564207 — Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Adults · Phase 2 · not yet recruiting
NCT06233110 — Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHD · Phase 1 · recruiting
NCT05904093 — Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Di · Phase 1 · recruiting
NCT05613296 — Real World Evaluation of the Activity and Safety of Fostamatinib in Consecutive Adult Patients With ITP · completed
NCT06071520 — Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study · completed

Other recruiting trials for Renal Transplant Rejection

Currently open trials in the same condition.

NCT03719339 — VIRTUUS Children's Study · active not recruiting

Other Imperial College London trials

Trials by the same sponsor.

NCT06035861 — Endothelial Cell Activation and Total Pulmonary Resistance in PAH · NA · not yet recruiting
NCT07397455 — Development of a Controlled Human Infection Model for Assessment of SARS-CoV-2 Omicron Subvariants · Phase 1 · not yet recruiting
NCT07422532 — A Multi-centre Trial to Assess the Efficacy and Safety of the Omnipod 5 System in People With Type 2 Diabetes Undergoing · NA · not yet recruiting
NCT07389031 — Maralixibat for Intrahepatic Cholestasis of Pregnancy · Phase 2 · not yet recruiting
NCT07358897 — Gender Affirming Hormone Therapy and Immune Function in Trans Individuals - The GIFT Study · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03991780 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imperial College London
Last refreshed: 25 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03991780.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing